Mode
Text Size
Log in / Sign up

16% of patients develop new endocrine deterioration after transsphenoidal surgery for non-functioning pituitary adenomasPituitary Surgery Linked to New Hormone Problems in 16%

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Consider tumour volume and resection extent when counseling patients on endocrine risks after NFPA surgery.

This meta-analysis pooled data from 2350 adults undergoing transsphenoidal surgery for non-functioning pituitary adenomas (NFPAs) to estimate the rate of new post-operative endocrine deterioration and identify predictive factors. The primary outcome was new endocrine deterioration, which occurred in 16% of patients (95% CI 13-20%; I² = 60%).

Among secondary outcomes, larger tumour volume was positively associated with deterioration, while gross total resection was associated with reduced odds of deterioration compared with subtotal resection. These associations were reported qualitatively without effect sizes or confidence intervals.

The authors noted that the overall certainty of evidence was low to very low, reflecting heterogeneity and potential bias. Follow-up duration was not reported, and no safety data were available.

Clinically, tumour volume emerged as the most consistent predictor of endocrine deterioration, suggesting a potential role for earlier intervention in selected patients. However, given the low certainty, these findings should be interpreted cautiously and not drive definitive practice changes.

A new analysis of 2,350 adults who had surgery for non-functioning pituitary adenomas (NFPAs) found that about 16% developed new endocrine problems, meaning their pituitary gland stopped making one or more hormones properly. This is the first large-scale look at how often this complication happens after this common surgery.

The analysis combined results from many studies, so it gives a clearer picture than any single study alone. The researchers also looked for factors that might predict who is more likely to have these hormone issues. They found that people with larger tumors were more likely to have problems. On the other hand, those who had the entire tumor removed (gross total resection) had lower odds of new hormone problems compared to those who had only partial removal.

It's important to note that the overall quality of the evidence was low to very low, meaning we can't be completely sure about these numbers. The studies varied a lot, and the analysis couldn't account for all differences between patients. Also, the analysis didn't report on other safety issues like bleeding or infection, so we don't have the full picture of risks.

For patients facing this surgery, the main takeaway is that while most people do not have new hormone problems, a significant minority do. If you're considering surgery, talk to your doctor about your individual risk, especially if you have a large tumor. This information might help you and your doctor make a more informed decision about timing and approach.

What this means for you:
About 16% of patients develop new hormone problems after pituitary tumor surgery; larger tumors increase risk.

Common questions

What is a non-functioning pituitary adenoma?

A non-functioning pituitary adenoma is a benign tumor of the pituitary gland that does not produce excess hormones. It can still cause problems by pressing on nearby structures, leading to symptoms like headaches or vision issues. Surgery is often done to remove it.

What does 'endocrine deterioration' mean?

Endocrine deterioration means the pituitary gland stops making one or more hormones properly after surgery. This can lead to conditions like hypothyroidism or adrenal insufficiency, which may require lifelong hormone replacement. In this analysis, 16% of patients experienced this.

Who is more likely to have hormone problems after surgery?

The analysis found that people with larger tumors were more likely to have new hormone problems. Also, those who had the entire tumor removed had lower odds compared to those with partial removal. However, the evidence is not strong, so individual risk varies.

Study Details

Study typeMeta analysis
Sample sizen = 2,350
EvidenceLevel 1
PublishedAug 2026
View Original Abstract ↓
BACKGROUND: Endoscopic transsphenoidal surgery is indicated when non-functioning pituitary adenomas (NFPAs) cause visual compromise, but its timing is less certain in patients with preserved vision and intact pituitary function, where the risk of new post-operative pituitary dysfunction influences decision-making. This systematic review aimed to determine the rate of new post-operative endocrine deficits following transsphenoidal surgery for NFPAs and to identify predictive factors. METHODS: This review followed PRISMA guidelines. Studies reporting predictors of post-operative endocrine deterioration in adults undergoing transsphenoidal surgery for NFPAs were included. Predictors were synthesised narratively, with meta-analysis where at least two studies used comparable definitions. Pooled proportions estimated the overall rate of deterioration. Certainty of evidence was assessed using GRADE. RESULTS: Eleven studies comprising 2,350 patients were included. The pooled proportion developing new post-operative endocrine deterioration was 16% (95% CI 13-20%; I² = 60%). Larger tumour volume was associated with deterioration, and gross total resection with reduced odds compared with subtotal resection. Cavernous sinus invasion and other predictors showed inconsistent associations, while age, sex, comorbidities, apoplexy, pituitary gland or stalk visibility, surgeon experience and surgical approach were not associated with risk. Overall certainty of evidence was low to very low. CONCLUSION: New post-operative endocrine deficits affect approximately one in six patients after transsphenoidal surgery for NFPAs. Tumour volume was the most consistent predictor of endocrine deterioration, suggesting a potential role for earlier intervention in selected patients, although evidence certainty was low to very low. Standardised reporting and prospective studies are needed to guide risk stratification decision-making.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.